Answer
Nivolumab (OPDIVO) is combined with ipilimumab for first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.
Sources for this answer
- OPDIVO 10 mg/mL concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.1 Therapeutic Indications · Version 67Document updated
Sources checked